Premium
Outcome of acute myeloid leukemia patients with pulmonary nodules of uncertain etiology receiving allogeneic hematopoietic progenitor cell transplant
Author(s) -
Lim Sara J.,
Lim Matthew J.,
Raptis Anastasios,
Hou JingZhou,
Farah Rafic,
Marks Stanley,
Im Annie,
Dorritie Kathleen,
Sehgal Alison,
Agha Mounzer,
Lim Seah H.
Publication year - 2016
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12547
Subject(s) - medicine , myeloid leukemia , etiology , gastroenterology , transplantation , hematopoietic stem cell transplantation , haematopoiesis , myeloid , progenitor cell , stem cell , surgery , genetics , biology
Pulmonary nodules ( PN s) develop frequently in patients with acute myeloid leukemia ( AML ). They are of infectious or inflammatory origin. They pose potential challenges to successful hematopoietic progenitor cell ( HPC ) transplant as they may be niches for infection reactivation or sites susceptible to subsequent infections. We retrospectively analyzed the outcome of 20 AML patients with multiple PN s who underwent allogeneic HPC transplants (12 related, 8 unrelated). There were 13 males and seven females (median age 52 yrs). Nine patients were in CR 1, seven in CR 2, and four with residual disease. The median times from appearance of PN s and from last positive CT scans to transplant were three and two months, respectively. The median time from pretransplant CT scans to transplant was one month. Multiple PN s were still reported in 5/20 of the pretransplant scans. The PN s in all five patients did not worsen after transplant. Four patients (one with positive pretransplant CT scan) died within the first 100 d after transplant, but none from primary pulmonary pathology. The median survival of this group of patients was 350 d. Our results, therefore, suggest that multiple PN s of uncertain etiology in patients with AML do not impact adversely on the outcome of allogeneic HPC transplant.